Good morning :)
$
₹
Celularity Inc

Celularity Inc

CELU

NASDAQ
Asset Logo

Celularity Inc

CELU

NASDAQ
$0.831.82% (+0.01)
$
₹
$0.831.82% (+0.01)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $26.0M the stock is ranked 5383

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

9.89
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.7
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-245.68%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Based on consolidated analysts reports

?

Buy, Sell and Hold recommendations are not available

Price Upside

—

Earnings Growth

—

Rev. Growth

—

Company Profile

Company Profile

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.67
50.67
1Y Return
36.27%
36.27%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.90
28.90
1Y Return
58.2%
58.2%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
37.21%
37.21%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
32.21
32.21
1Y Return
24.59%
24.59%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.24
21.24
1Y Return
51.74%
51.74%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

Financials

Financials

Income

Balance Sheet

Cash Flow

4.1
-24.3
4.1
-24.3
3.8
0.8
5.4
0.7
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue12.119.2918.1318.135.735.284.104.103.845.43
Net Income9.54-16.09-13.29-13.29-24.52-23.07-24.36-24.360.870.70
Net Profit Margin78.82%-173.17%-73.31%-73.31%-427.54%-436.71%-593.61%-593.61%22.72%12.99%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Celularity Inc -9.89-
AbbVie Inc50.6750.450.60
Amgen Inc28.9021.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare CELU with any stock or ETF
Compare CELU with any stock or ETF
Comparing from
CELU
ABBV
AMGN
Loading...

Frequently asked questions

  1. Celularity Inc (CELU) share price today is $0.83 as of November 5, 2026 at 1:19 AM IST. The stock touched a day high of $0.85 and a day low of $0.83.

  2. Celularity Inc stock trades on NASDAQ under the ticker symbol CELU.

  3. Celularity Inc's market capitalization is $26.04M as of November 5, 2026 at 1:19 AM IST.

  4. Celularity Inc's price-to-earnings (P/E) ratio is N/A as of November 4, 2026.

  5. Celularity Inc's price-to-book (P/B) ratio is 9.89 as of November 4, 2026.

  6. Yes, You can buy Celularity Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Celularity Inc shares in three steps: 1. Search Celularity Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Celularity Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Celularity Inc (CELU) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 12.0192 shares at the current price of $0.83.

Loading...